Questions? +1 (202) 335-3939 Login
Trusted News Since 1995
A service for medical industry professionals · Friday, March 29, 2024 · 699,728,756 Articles · 3+ Million Readers

Chronic inflammatory demyelinating polyneuropathy (CIDP) Pharmaceutical and Healthcare Pipeline Review H2

Chronic inflammatory demyelinating polyneuropathy (CIDP) Therapeutic and Disease Pipeline Review H2

PUNE , INDIA, February 16, 2018 /EINPresswire.com/ -- Summary
Chronic inflammatory demyelinating polyneuropathy (CIDP) also called as chronic relapsing polyneuropathy is a neurological disorder characterized by progressive weakness and impaired sensory function in the legs and arms. The disease is caused by damage to the myelin sheath of the peripheral nerves. Symptoms include initial limb weakness, both proximal and distal, orthostatic dizziness, tingling and numbness of hands and feet.

GET SAMPLE REPORT @ https://www.wiseguyreports.com/sample-request/2989080-chronic-inflammatory-demyelinating-polyneuropathy-cidp-pipeline-review-h1-2018

Report Highlights
Pharmaceutical and Healthcare latest pipeline guide Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase I and Preclinical stages are 1, 4, 1 and 2 respectively.

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantageAdditionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) (Central Nervous System).
- The pipeline guide reviews pipeline therapeutics for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) (Central Nervous System) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) (Central Nervous System)

Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) (Central Nervous System).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) (Central Nervous System) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Content: Key Points
List of Tables
List of Figures
Introduction
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Overview
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Therapeutics Assessment
Assessment by Target
Assessment by Route of Administration
Assessment by Molecule Type
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Companies Involved in Therapeutics Development
CSL Ltd
GeNeuro SA
Momenta Pharmaceuticals Inc
Octapharma AG
Pfizer Inc
Shire Plc
Teijin Pharma Ltd
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Drug Profiles
GL-2045 - Drug Profile
Product Description
…Continued

ACCESS REPORT @ https://www.wiseguyreports.com/reports/2989080-chronic-inflammatory-demyelinating-polyneuropathy-cidp-pipeline-review-h1-2018

Get in touch:
LinkedIn: www.linkedin.com/company/4828928
Twitter: https://twitter.com/WiseGuyReports
Facebook: https://www.facebook.com/Wiseguyreports-1009007869213183/?fref=ts

Norah Trent
wiseguyreports
+1 646 845 9349 / +44 208 133 9349
email us here

Powered by EIN Presswire


EIN Presswire does not exercise editorial control over third-party content provided, uploaded, published, or distributed by users of EIN Presswire. We are a distributor, not a publisher, of 3rd party content. Such content may contain the views, opinions, statements, offers, and other material of the respective users, suppliers, participants, or authors.

Submit your press release